Biliothoracic Fistula after Microwave Ablation of Liver Metastasis: Literature Review

Valentina Tassi 1, Claudia Mosillo 2, Massimiliano Mutignani 3, Roberto Cirocchi 4, Mark Ragusa 1, Sergio Bracarda 2, Giovanni Passalacqua 5, Gabriele Marinozzi 6, and Massimiliano Allegritti 5

1 Thoracic Surgery Unit, Azienda Ospedaliera Santa Maria, Terni, Italy
2 Medical and Translational Oncology Unit, Azienda Ospedaliera Santa Maria, Terni, Italy
3 Digestive Endoscopic Unit, Ospedale Niguarda, Milano, Italy
4 Department of Medicine and Surgery, University of Perugia, Perugia, Italy
5 Division of Interventional Radiology, Azienda Ospedaliera Santa Maria, Terni, Italy
6 Digestive Endoscopic Unit, Azienda Ospedaliera Santa Maria, Terni, Italy

Correspondence should be addressed to Roberto Cirocchi; roberto.cirocchi@unipg.it

Received 29 March 2021; Accepted 3 May 2021; Published 12 May 2021

Academic Editor: Canan Akman

Copyright © 2021 Valentina Tassi et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Microwave ablation is a safe and effective interventional approach, widely used in the treatment of unresectable primary or metastatic hepatic lesions. Biliothoracic fistula (TBF) is a rare postablation complication characterized by relevant mortality and morbidity rates [4, 5]. TBF may communicate with either the pleural space (pleurobiliary fistula, PBF) or the bronchi (bronchobiliary fistula, BBF) [6]. Treatment options include surgery, with thoracoabdominal exploration, and conservative therapy characterized by percutaneous transhepatic (PT) or endoscopic retrograde cholangiopancreatography (ERCP) biliary drainage [6–8]. To date, guidelines for the optimal approach of TBF are lacking [7].

We report our experience on combined BPF and BBF treated conservatively in a patient with CRC single liver metastasis undergone MWA.

1. Biliothoracic Fistula

Almost 30% of patients with metastatic colorectal cancer (CRC) present with liver metastases only. Although surgical resection is the most effective treatment, patients with isolated CRC liver lesions, deemed to be unresectable, may benefit from thermal ablation (Radiofrequency Ablation, RA, and Microwave Ablation, MWA) or Trans-Arterial Chemoembolization (TACE) [1–3].

Thoracobiliary fistula (TBF) is a rare postablation complication characterized by relevant mortality and morbidity rates [4, 5]. TBF may communicate with either the pleural space (pleurobiliary fistula, PBF) or the bronchi (bronchobiliary fistula, BBF) [6]. Treatment options include surgery, with thoracoabdominal exploration, and conservative therapy characterized by percutaneous transhepatic (PT) or endoscopic retrograde cholangiopancreatography (ERCP) biliary drainage [6–8]. To date, guidelines for the optimal approach of TBF are lacking [7].

We report our experience on combined BPF and BBF treated conservatively in a patient with CRC single liver metastasis undergone MWA.

2. Our Experience

In January 2020, a 73-year-old man with a history of metachronous and unresectable CRC liver metastasis (Figure 1) was admitted to our center because of fatigue and shortness of breath. Since March 2016, the patient has been treated with a multidisciplinary approach characterized by chemotherapy plus targeted therapy and MWA. In particular, MWA of the single hepatic lesion at segment V was performed twice: in October 2016 and November 2019.
At the time of admission, the chest X-rays showed right-side pleural effusion (Figure 2(a)) and the thoracentesis revealed bilious fluid; thus, a chest drainage was inserted. A chest and abdomen CT scan confirmed the pleural effusion and revealed postablation liver damage (Figure 2(b)). The clinical hypothesis of BPF was demonstrated by means of ERCP with contrast extravasation from the liver towards the pleural cavity (Figure 2(c)). After sphincterotomy, a bilioduodenal endoprosthesis and multiple biliary stents (AdvanixBiliary stent-Boston Scientific® 10 Fr x 12 cm) were placed to decompress the intrahepatic biliary system adjacent the ablated lesion (Figure 3(a)–3(c)). After this procedure, the amount of biliary fluid from the chest tube progressively decreased and chest X-rays demonstrated the reduction of pleural effusion; thus, the chest tube was removed after two weeks, and the patient was discharged home. Ten days later, he was readmitted at our hospital with fever, dyspnea, and productive cough with greenish sputum. Blood examination showed elevated value of white blood cells count and C-reactive protein. Bacteriaculture of blood revealed Enterococcus faecium. The chest and abdomen CT scan showed a large lung abscess of the middle lobe communicating with a bilioma of the hepatic segments V–VIII by means of a long and thin BBF (Figure 4(a)). The aforementioned findings were confirmed by the percutaneous cholangiography. This exam revealed a “Y”-shaped fistula originating from the intrahepatic bilioma and dividing in two arms which reached separately the pleural space (BPF) and the middle lobe abscess up to one segmental bronchus (BBF). Moreover, bilioduodenal endoprosthesis obstruction was observed (Figure 4(b)). Immediately, the pleural space and the middle lobe abscess were drained by two chest tubes (10Fr pigtail) and appropriate antibiotic therapy was started. In order to minimize the pressure in the biliary tree and prevent the bile flow through the TBF, we drained the bilioma with a 10Fr pigtail catheter and we introduced a percutaneous transhepatic biliary drainage (10Fr pigtail) with a percutaneous transhepatic approach. Regarding the BBF and BPF, we decided to treat them with percutaneous synthetic glue embolization (Glubran mixed with Lipiodol 1 : 3). Sixteen days after, there was no evidence ofBBF and BPF at percutaneous cholangiography (Figure 5(a)). Consequently, we decided to remove both chest and abdomen drainages. Presently, the patient is alive and free from cancer recurrence 14 months after the last liver metastasis MWA and almost 5 years after the diagnosis of CRC (Figures 5(b) and 5(c)).

Written informed consent was obtained from the patient. All procedures were in accordance with the ethical standards of the institutional and national research committees and with the Helsinki Declaration, as revised in 2013.

3. Discussion and Literature Review

For patients not eligible for surgery, MWA can be offered as a valid alternative option for liver metastasis from CRC [1–3]. Despite its safe profile, MWA may have several complications including vascular injury, biliary damage, and infections [4]. The incidence of biliary tract thermal ablation complications (e.g., biliary strictures, bilomas, and bile leaks) ranges between 0.1% and 12% of cases, and TBF are exceedingly rare [5, 7, 9]. Postablative tissue inflammation can be considered the main trigger process causing adhesion between the liver and diaphragm. Furthermore, the biliary stricture and the intrapleural pressure lower than abdominal pressure play a role in the fistula formation and favor the flow of bile toward the pleural space. Consequently, the risk of this complication is higher when treating voluminous lesions located near the diaphragm (i.e., lesions in hepatic segments VII or VIII) [10–13].

Despite the diffusion of thermal ablation for the treatment of liver metastases, the literature reports higher rates of postablative TBF in patients with primary hepatic tumor than in patients with secondary liver lesions [8, 12, 14]. We speculate that hepatocarcinoma and intrahepatic cholangiocarcinoma are often voluminous and sub-diaphragmatic lesions with consequently high risk of bile leaks.

The diagnosis of TBF is based on radiologic imaging. CT scan and magnetic resonance, indeed, can show indirect signs of biliopleural communication as pleural effusion, intrahepatic bile duct dilatation, and postprocedure liver...
damage close to the diaphragm. Conversely, cholangiography is the procedure of choice to identify the biliary leak. The combination of pathognomonic clinical symptoms, a history of recent locoregional liver procedure, and radiological imaging, guide the diagnosis [10, 15, 16].

The optimal treatment for TBF is far to be defined [7, 16]. Although the surgical approach based on debridement and ductal repair has been long advocated [6, 12], less-invasive treatments have recently developed [16–18]. None of the patients with postablative TBF for liver metastasis described in the literature underwent surgery (Table 1) [14, 16–20]. The

Figure 2: Chest plain radiograph 2 months after MWA showing a right pleural effusion (a); CT scan revealing a hypodense oval lesion of 48 × 33 mm with hyperdense core consistent with postablation liver damage (b); and ERCP demonstrating contrast leakage from right-sided bile duct (arrow) and extravasation of contrast into the right pleural cavity (C).

Figure 3: Endoscopic treatment of the BPF by means of a large sphincterotomy (a), placement of two biliary stents (Advantis Biliary stent, Boston Scientific® 10 Fr × 12 cm) to decompress the right bile duct (b), and a bilioduodenal endoprosthesis (c).

Figure 4: Chest-abdomen CT scan showing a 50 mm-diameter abscess of the middle lobe communicating with the subsegmental bronchi (arrow) (a); percutaneous cholangiography revealing a “Y”-shaped fistula originating from intrahepatic bilioma (blue arrow) and divided in two arms which reached separately the pleural space (red arrow) and the middle lobe abscess up to one segmental bronchus (yellow arrow) (b).
A conservative approach is aimed to decrease the pressure in the biliary tree and to prevent the flow of bile through the TBF, enhancing its closure [7]. Biliary drainage can be performed by ERCP with endoprosthesis or stent placement or by means of the PT approach [17–20]. Synthetic glue treatment is a minimally invasive and safe technique, already used for endoscopic cure of gastrointestinal fistula and as an embolizing agent in interventional radiology and vascular neuroradiology. The successful use of Glubran® glue to seal the TBF is described in few reports [16].

4. Conclusions

TBF is a rare postablation complication characterized by relevant mortality and morbidity rates. The diagnosis of TBF requires a high index of suspicion. Indeed, early detection and conservative management with biliary drainage may prevent severe sequelae. The current case highlights the successful management of an iatrogenic, nonhealing TBF. We initially decided to decompress the biliary system with endoscopic stent placement. However, this method offered a short-term benefit followed by pleural effusion recurrence complicated by BBF. Percutaneous drainages, biliary decompression, and the injection of glue in both BBF and PBF resulted in prompt resolution of biloptysis and pleural effusion. Glubran® glue embolization of the TBF is effective, safe, and should be considered for the treatment of TBF before recourse to surgery.

Data Availability

The data used to support the findings of this study are available from the corresponding author upon request.

Conflicts of Interest

The authors declare that they have no conflicts of interest.

References

[1] P. Kron, M. Linecker, R. P. Jones et al., “Ablation or resection for colorectal liver metastases? A systematic review of the literature,” Front Oncol, vol. 9, Article ID 1052, 2019.
[2] R. Adam, A. de Gramont, J. Figueras et al., “Managing synchronous liver metastases from colorectal cancer: a multidisciplinary international consensus,” Cancer Treatment Reviews, vol. 41, no. 9, pp. 729–741, 2015.
[3] T. Ruers, F. Van Coevorden, C. J. A. Punt et al., “Local treatment of unresectable colorectal liver metastases: results of a randomized phase II trial,” INCI: Journal of the National Cancer Institute, vol. 109, no. 9, Article ID dxj015, 2017 1.
[4] C. Fang, K. Cortis, G. T. Yusuf et al., “Complications from percutaneous microwave ablation of liver tumours: a pictorial review,” The British Journal of Radiology, vol. 92, no. 1099, Article ID 20180864, 2019.
[5] S. A. Curley, P. Marra, K. Beaty et al., “Early and late complications after radiofrequency ablation of malignant liver tumors in 608 patients,” Annals of Surgery, vol. 239, no. 4, pp. 450–458, 2004.
[6] A. Crnjac, V. Pivec, and A. Ivanecz, “Thoracobiliary fistulas: literature review and a case report of fistula closure with omentum majus,” *Radiology and Oncology*, vol. 47, no. 1, pp. 77–85, 2013.

[7] B. Singh, J. Moodley, M. H. Sheik-Gafoor, N. Dhooma, and A. Reddi, “Conservative management of thoracobiliary fistula,” *The Annals of Thoracic Surgery*, vol. 73, no. 4, pp. 1088–1091, 2002.

[8] G.-Q. Liao, H. Wang, G. Y. Zhu et al., “Management of acquired bronchobiliary fistula: a systematic literature review of 68 cases published in 30 years,” *World Journal of Gastroenterology*, vol. 17, no. 33, pp. 3842–3849, 2011.

[9] S. H. Kim, H. K. Lim, D. Choi et al., “Changes in bile ducts after radiofrequency ablation of hepatocellular carcinoma: frequency and clinical significance,” *American Journal of Roentgenology*, vol. 183, no. 6, pp. 1611–1617, 2004.

[10] Z. M. Huang, M. X. Zuo, Y. K. Gu et al., “Bronchobiliary fistula after ablation of hepatocellular carcinoma adjacent to the diaphragm: case report and literature review,” *Thoracic Cancer*, vol. 11, no. 5, pp. 1233–1238, 2020.

[11] D. H. Yoon, J. H. Shim, W. J. Lee, P. N. Kim, J. H. Shin, and K. M. Kim, “Percutaneous management of a bronchobiliary fistula after radiofrequency ablation in a patient with hepatocellular carcinoma,” *Korean Journal of Radiology*, vol. 10, no. 4, pp. 411–415, 2009.

[12] Z. Zeng, M. Cai, W. Huang et al., “Delayed bronchobiliary fistula following radiofrequency ablation in a patient with hepatocellular carcinoma: a case report and lesson regarding treatment,” *Oncology Letters*, vol. 11, no. 5, pp. 3213–3217, 2016.

[13] S. G. Delis, D. Karakaxas, A. Bakoyiannis, K. Paraskeva, and C. Dervenis, “Pleurobiliary fistula, a rare complication of hepatocellular carcinoma after locoregional chemotherapy: a case report,” *Cases Journal*, vol. 2, no. 1, p. 7992, 2009.

[14] X. J. Xi, Y. Zhang, Y. H. Yin, H. Li, D. D. Ma, and Y. Q. Qu, “Bronchobiliary fistula following radiofrequency ablation for liver metastases from breast cancer: a case report and literature review,” *Medicine (Baltimore)*, vol. 97, no. 43, Article ID e12760, 2018.

[15] H. Eryigit, S. Oztas, S. Urek, G. Olgac, M. Kurutepe, and C. A. Kutlu, “Management of acquired bronchobiliary fistula: 3 case reports and a literature review,” *Journal of Cardiothoracic Surgery*, vol. 2, p. 52, 2007.

[16] N. Pinsker, M. Papoulas, M. Sodergren, P. Harrison, N. Heaton, and K. Menon, “Successful endoscopic management of a persistent bronchobiliary fistula with Histoacryl/Lipiodol mixture,” *The Annals of The Royal College of Surgeons of England*, vol. 100, no. 4, pp. e73–e77, 2018.

[17] Y.-S. Kim, H. Rhim, J. H. Sung et al., “Bronchobiliary fistula after radiofrequency thermal ablation of hepatic tumor,” *Journal of Vascular and Interventional Radiology*, vol. 16, no. 3, pp. 407–410, 2005.

[18] V. Pende, M. Marchese, M. Mutignani et al., “Endoscopic management of biliopleural fistula and biloma after percutaneous radiofrequency ablation of liver metastasis,” *Gastrointestinal Endoscopy*, vol. 66, no. 3, pp. 616–618, 2007.

[19] G. Liberale, M. Delhaye, J. Ansay et al., “Biliary pleural fistula as a complication of radiofrequency ablation for liver metastasis,” *Acta Chirurgica Belgica*, vol. 104, no. 4, pp. 448–450, 2004.

[20] T. Tran, H. Hampel, W. A. Qureshi, and Y. Shaib, “Successful endoscopic management of bronchobiliary fistula due to radiofrequency ablation,” *Digestive Diseases and Sciences*, vol. 52, no. 11, pp. 3178–3180, 2007.